Levi & Korsinsky Alerts Intellia Therapeutics Investors About Class Action Lawsuit and Important Deadline

Levi & Korsinsky Alerts Intellia Therapeutics Investors

On March 28, 2025, Levi & Korsinsky, LLP announced an important update for investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) through a class action lawsuit concerning potential securities fraud.

Investors who were affected between July 30, 2024, and January 8, 2025, may have the chance to claim damages following the allegations detailed in the legal complaint. The lawsuit aims to recover losses experienced by those investors as a result of significant misrepresentation related to Intellia's research initiatives.

Class Action Overview

The class action complaint centers around statements made by the company regarding its Phase 1/2 clinical study of NTLA-3001, intended to treat alpha-1 antitrypsin deficiency-related lung disease. The defendants, identified as leaders within Intellia, purportedly provided misleading assurances about the development timeline of the study, suggesting the first patient would be dosed in the latter half of 2024. However, it has now come to light that they failed to disclose critical information indicating a sharp decline in demand for viral-based editing technologies, as the industry increasingly shifted focus towards more efficient and cost-effective non-viral delivery methods.

On January 9, 2025, the truth became apparent when Intellia issued a press release detailing a company reorganization. The announcement included the cessation of all NTLA-3001 research and a significant reduction of the workforce, with plans to implement cost-saving measures. Following this revelation, Intellia's stock price fell sharply, descending from $12.02 per share at market close on January 8 to $10.20 per share by January 10, reflecting investors' concerns over the company's future prospects.

Next Steps for Investors

For those who experienced losses during the stated period, it is essential to take appropriate action promptly. Potential lead plaintiffs have until April 14, 2025, to submit their requests to be appointed as lead plaintiffs in this case. Notably, participating in any potential recovery does not require being a lead plaintiff, making it crucial for all affected investors to explore their options.

Moreover, there's no cost associated with joining this class action for eligible investors. Those classified as members of this class may receive compensation without incurring any out-of-pocket costs.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has established a strong reputation for winning high-stakes securities litigation over the past two decades, securing hundreds of millions for aggrieved shareholders. With a dedicated team of over 70 employees, the firm has extensive experience representing investors in complex securities litigation. It has consistently ranked among the top securities litigation firms in the United States, according to ISS Securities Class Action Services' Top 50 Report for seven consecutive years.

Contact Information

Investors seeking additional information or wishing to discuss their rights further can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email at [email protected] or call (212) 363-7500. Interested parties can also visit their official website for more resources and information regarding the ongoing lawsuit.

As an investor, it is critical to stay informed and know your rights, especially during times of uncertainty caused by corporate misjudgments. This class action lawsuit represents a vital opportunity for those who have been impacted to seek justice and recover their losses incurred due to alleged securities fraud by Intellia Therapeutics.